Loading
A phase 3 trial of Abiraterone acetate, Prednisone in prostate cancer, run by Jiangsu HengRui Medicine Co., Ltd., active and no longer recruiting.
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer is a phase 3 interventional study registered as NCT04691804 by Jiangsu HengRui Medicine Co., Ltd., with 496 participants enrolled, started 2021-03-18 and due to reach its primary completion in 2026-12-31. Interventions recorded: Fuzuloparib , Abiraterone acetate and Prednisone, Fuzuloparib Placebo， Abiraterone acetate and Prednisone. Conditions listed: Metastatic Castration-Resistant Prostate Cancer (mCRPC). No results are recorded here; the registry entry is the source.
Shares Abiraterone acetate, Androgen deprivation & AR pathway inhibitors, Prostate cancer.
Shares Prednisone, Jiangsu Hengrui Pharmaceuticals, Prostate cancer.
Shares Abiraterone acetate, Prednisone, Metastatic castration-resistant prostate cancer, Prostate cancer.
Shares Abiraterone acetate, Prednisone, Prostate cancer.
Shares Abiraterone acetate, Androgen deprivation & AR pathway inhibitors, Prednisone, Prostate cancer.
Shares Abiraterone acetate, Androgen deprivation & AR pathway inhibitors, Prednisone, Metastatic castration-resistant prostate cancer.
Shares Abiraterone acetate, Prednisone, Prostate cancer.
Shares Androgen deprivation & AR pathway inhibitors, Metastatic castration-resistant prostate cancer, Prostate cancer.